Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ADRO

Aduro Biotech (ADRO) Stock Price, News & Analysis

Aduro Biotech logo

About Aduro Biotech Stock (NASDAQ:ADRO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$2.28
$14.60
52-Week Range
N/A
Volume
171,500 shs
Average Volume
162,237 shs
Market Capitalization
$236.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ADRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aduro Biotech and its competitors with MarketBeat's FREE daily newsletter.

ADRO Stock News Headlines

Aduro Clean Technologies Inc.
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
ACTHD Aduro Clean Technologies Inc.
Aduro Clean Technologies Inc Ordinary Shares
PT Adaro Energy Indonesia Tbk
PT Adaro Energy Indonesia Tbk ADRO
See More Headlines

ADRO Stock Analysis - Frequently Asked Questions

Aduro Biotech, Inc. (NASDAQ:ADRO) announced its quarterly earnings data on Monday, May, 4th. The biotechnology company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. The biotechnology company had revenue of $13.95 million for the quarter, compared to the consensus estimate of $8.81 million. Aduro Biotech had a negative net margin of 230.92% and a negative trailing twelve-month return on equity of 101.73%.

Aduro Biotech (ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aduro Biotech investors own include Regulus Therapeutics (RGLS), Exact Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Anavex Life Sciences (AVXL), VBI Vaccines (VBIV) and Amarin (AMRN).

Company Calendar

Last Earnings
5/04/2020
Today
8/06/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADRO
CIK
1435049
Fax
N/A
Employees
152
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($5.15)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$82.37 million
Net Margins
-230.92%
Pretax Margin
N/A
Return on Equity
-101.73%
Return on Assets
-22.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.91
Quick Ratio
8.91

Sales & Book Value

Annual Sales
$17.26 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.07 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
16,212,000
Free Float
N/A
Market Cap
$236.61 million
Optionable
Optionable
Beta
0.40
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:ADRO) was last updated on 8/6/2025 by MarketBeat.com Staff
From Our Partners